TY-9591（氘代奥希替尼衍生物）在晚期EGFR突变非小细胞肺癌中的安全性、药代动力学和疗效：一项1期剂量递增和剂量扩展研究

文章预览

SCI 3 February 2025 Safety, Pharmacokinetics, and Efficacy of TY-9591 (Deuterated Osimertinib Derivative) in Advanced EGFR-mutated Non-Small Cell Lung Cancer: A Phase 1 Dose-Escalation and Dose-Expansion Study (Journal of Thoracic Oncology, IF: 21.1) Baohui Han, Jie Liu, Lin Wu, Yanqiu Zhao, Wei Zhang, Bolin Chen, Jianbo He, Jianhua Shi, Yanqing Liu, Zhe Zhang, Xiugui Chen, Yusheng Wu CORRESPONDENCE TO: 18930858216@163.com Background 背景 This phase 1 study evaluated the safety, pharmacokinetics, and preliminary efficacy of TY-9591 (asandeutertinib), a deuterated osimertinib derivative. 本1期研究评估了TY-9591（氘代奥希替尼衍生物）的安全性、药代动力学及初步疗效。 Methods 方法 Patients with advanced EGFR-mutated (most commonly exon 19 deletions or L858R) non-small cell lung cancer (NSCLC) were enrolled. In the dose-escalation phase, TY-9591 was administered from 20 mg to 200 mg once daily to assess doselimiting toxicities (DLTs) and the maximum tol ………………………………